AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28116801
Drug: oral ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral ezetimibe 10 mg daily
Trial: 23994369
Drug: 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) at 500 mg/kg
Trial: 23994369
Drug: Allopurinol at
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol at 500 mg/kg
Trial: 21489570
Drug: Almonds (28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds (28 g) consumed with a standardized meal
Trial: 11768838
Drug: Almotriptan 6
RxNorm normalized name: almotriptan 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 6 mg
Trial: 11768838
Drug: Almotriptan 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 10 mg
Trial: 29688615
Drug: Bococizumab 150
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 150 mg subcutaneous injection via prefilled syringe (PFS) using drug substance manufactured by Pfizer
Trial: 29688615
Drug: Bococizumab 150
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 150 mg subcutaneous injection via prefilled syringe (PFS) using drug substance manufactured by Boehringer Ingelheim Pharma
Trial: 29688615
Drug: Bococizumab 150
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 150 mg subcutaneous injection via prefilled pen using drug substance manufactured by Pfizer
Trial: 29688615
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PFS by Pfizer, PFS by Boehringer Ingelheim, prefilled pen by Pfizer)
Trial: 29449189
Drug: Chemoradiotherapy (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (radiotherapy plus chemotherapy consisting of two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Trial: 24220749
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg administered 1 h preoperatively
Trial: 24220749
Drug: Placebo 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 200 mg administered 1 h preoperatively
Trial: 17434845
Drug: FOTO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOTO treatment schedule (5 days on, 2 days off)
Trial: 17434845
Drug: FOTO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOTO treatment schedule with efavirenz-based regimens
Trial: 17434845
Drug: FOTO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOTO treatment schedule
Trial: 15154088
Drug: FSH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH treatment (n=24)
Trial: 12243815
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) by protracted venous infusion
Trial: 2803403
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or four inhalant anti-asthmatic drugs
Trial: 1125119
Drug: QX-572 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QX-572 (8 mg/kg body weight intravenously over 30 minutes)
Trial: 27129183
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg followed by 0.5 mg 1 hour later)
Trial: 10341163
Drug: D-tagatose (29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-tagatose (29 g)
Trial: 10341163
Drug: Sucrose (29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (29 g)
Trial: 6793298
Drug: LNG‐containing preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG‐containing preparation
Trial: 6793298
Drug: NET or
RxNorm normalized name: lactase / rennet Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NET or EDA preparations
Trial: 6793298
Drug: LNG preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG preparation
Trial: 20336327
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) during intravenous chemotherapy
Trial: 20336327
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no VR during intravenous chemotherapy)
Trial: 18292082
Drug: 4% amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% amethocaine gel (AnGEL)
Trial: 16542370
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily for 14 days
Trial: 10634372
Drug: Orbital radiotherapy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiotherapy (telecobalt) in 20 fractions of 1 Gray (Gy) weekly over 20 weeks (group A)
Trial: 10634372
Drug: Orbital radiotherapy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiotherapy (telecobalt) in 10 fractions of 1 Gy daily over 2 weeks (group B)
Trial: 10634372
Drug: Orbital radiotherapy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiotherapy (telecobalt) in 10 fractions of 2 Gy daily over 2 weeks (group C)
Trial: 7960186
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment preceding gamete recovery
Trial: 7960186
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of peroxidase-positive cells (> 6 x 10(6)/ml)
Trial: 3296741
Drug: Metolazone-furosemide combination
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metolazone-furosemide combination
Trial: 3296741
Drug: Thiazide-furosemide combination
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiazide-furosemide combination
Trial: 29089415
Drug: Periprocedural heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprocedural heparin (HEP+)
Trial: 20056180
Drug: S. sonnei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. sonnei conjugate (25 microg, injected IM twice, 6 weeks apart)
Trial: 20056180
Drug: S. flexneri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. flexneri 2a conjugate (25 microg, injected IM twice, 6 weeks apart)
Trial: 12196364
Drug: CTC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC chemotherapy (high-dose cyclophosphamide, thiotepa, carboplatin)
Trial: 12196364
Drug: FEC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC chemotherapy (standard-dose fluorouracil, epirubicin, cyclophosphamide)
Trial: 12196364
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy (conventional cyclophosphamide, methotrexate, 5-fluorouracil)
Trial: 7650223
Drug: Draflazine 2
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Draflazine 2 mg
Trial: 7650223
Drug: Draflazine 4
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Draflazine 4 mg
Trial: 7650223
Drug: Draflazine 6
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Draflazine 6 mg
Trial: 795440
Drug: D-oxazepam hemisuccinate
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-oxazepam hemisuccinate sodium salt (100 mg i.m.)
Trial: 795440
Drug: Racemic form
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic form of D-oxazepam (100 mg i.m.)
Trial: 7012246
Drug: Intraventricular amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraventricular amikacin (5 mg via Rickham reservoir)
Trial: 7012246
Drug: Intraventricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular therapy
Trial: 28831839
Drug: Customized sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized sound therapy
Trial: 28831839
Drug: Broadband noise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broadband noise therapy
Trial: 19893125
Drug: Intranasal electrophoresis
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal electrophoresis of vanadium
Trial: 15096905
Drug: Amlodipine 2.5
RxNorm normalized name: amlodipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5 mg per day
Trial: 11966786
Drug: Mucopolysaccharide-cartilage complex
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucopolysaccharide-cartilage complex (MCC) healing ointment
Trial: 18310201
Drug: Aquaphor ointment
RxNorm normalized name: Aquaphor Ointment Topical Body Spray
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquaphor ointment
Trial: 7666251
Drug: Wheat bread-based
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bread-based diet (daily intake 274 g starch, 2.4 g enzyme-resistant starch, 14.4 g total dietary fiber)
Trial: 7666251
Drug: Oat bran-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran-based diet (daily intake 243 g starch, 2.7 g enzyme-resistant starch, 40.2 g total dietary fiber)
Trial: 2711724
Drug: Intracervical Prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical Prostaglandin E2 (PGE2) gel application within 6 hours after PROM
Trial: 2711724
Drug: Intracervical Prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical Prostaglandin E2 (PGE2) gel application within 7-12 hours after PROM
Trial: 2711724
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion after 12 hours of waiting
Trial: 798636
Drug: Formalin‐inactivated cholera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalin‐inactivated cholera vaccine
Trial: 798636
Drug: Partially purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially purified toxoid preparation
Trial: 798636
Drug: Whole‐cell heat‐killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐cell heat‐killed cholera vaccine
Trial: 798636
Drug: Whole‐cell heat‐killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐cell heat‐killed El Tor vaccine
Trial: 29078762
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment program for high fracture risk women in the intervention group, based on screening program including FRAX, DXA, and IVA.
Trial: 26630467
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg daily for 14 days postoperatively
Trial: 26630467
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Aspirin and Control)
Trial: 17325089
Drug: Intravenous ampicillin/sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin/sulbactam for 48 hours followed by oral amoxicillin/clavulanate for 7 days
Trial: 17325089
Drug: Clindamycin for
RxNorm normalized name: Clindamycin for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin for 48 hours followed by oral clindamycin for 7 days
Trial: 15361375
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (non-adherent group)
Trial: 15361375
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methotrexate (non-adherent group)
Trial: 12047964
Drug: de Gramont
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: de Gramont regimen (folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days 1 and 2, repeated every 14 days)
Trial: 12047964
Drug: Lokich regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lokich regimen (protracted venous infusion of fluorouracil 300 mg/m(2) daily)
Trial: 12047964
Drug: raltitrexed (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raltitrexed (3 mg/m(2) intravenously every 21 days)
Trial: 9474447
Drug: High-dose ECT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ECT (2.5 x threshold)
Trial: 7699188
Drug: High-fat, high-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat, high-energy nutrition supplement consumed at a maximum of 30% of estimated daily energy requirements
Trial: 7699188
Drug: High-fat, high-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat, high-energy nutrition supplement
Trial: 29058112
Drug: Glutamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 0.25 g kg‐1 FFM
Trial: 29058112
Drug: Glutamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 0.5 g kg‐1 FFM
Trial: 29058112
Drug: Glutamine 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 0.9 g kg‐1 FFM
Trial: 17349882
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day of atorvastatin
Trial: 17349882
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of ezetimibe plus 10 mg/day of atorvastatin
Trial: 15292365
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (250 microg/hr)
Trial: 3622197
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LPD) group, 0.71 ± 0.12 g X kg‐1 X day‐1 protein for 4.5 ± 1 months
Trial: 3622197
Drug: Normal-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein diet (NPD) group, 1.44 ± 0.12 g X kg‐1 X day‐1 protein for 11.7 ± 7 months
Trial: 24243080
Drug: EMLA(®) 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA(®) 5% cream
Trial: 16204662
Drug: Pulmonary artery
RxNorm normalized name: Pulmonary artery blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary artery catheter (PAC) guided therapy
Trial: 10396888
Drug: Interdisciplinary psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary psychoeducational family group intervention (7 weekly, 2-hour sessions)
Trial: 1539456
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis DTP vaccine containing 12.5 micrograms (AC-12.5)
Trial: 1539456
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis DTP vaccine containing 25 micrograms (AC-25)
Trial: 1539456
Drug: Acellular vaccines
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccines (AC-12.5 and AC-25)
Trial: 1539456
Drug: Acellular vaccine
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccine (AC-12.5)
Trial: 3104512
Drug: Prophylactic i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic i.v. nitroglycerin at a dose of 0.7 microgram/kg‐1/min‐1
Trial: 31557492
Drug: PF-5190457 (GHS-R1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-5190457 (GHS-R1a inverse agonist)
Trial: 27132086
Drug: Standard abortive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard abortive or preventive antimigraine treatment (n=7)
Trial: 10884878
Drug: Trimethoprim‐sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim‐sulfamethoxazole (160 mg trimethoprim, 800 mg sulfamethoxazole)
Trial: 2185962
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg, orally, twice daily for 4 weeks)
Trial: 2185962
Drug: Placebo (orally,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally, twice daily for 4 weeks)
Trial: 6996660
Drug: Oral practolol
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral practolol 200 mg twice daily
Trial: 12211224
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg bid)
Trial: 23439357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ulinastatin and tranexamic acid
Trial: 12601217
Drug: 1.0 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mol/L gadobutrol
Trial: 12601217
Drug: 0.5 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mol/L gadobutrol
Trial: 10672435
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of controlled‐release melatonin
Trial: 7952047
Drug: L-alpha-glycerophosphorylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alpha-glycerophosphorylcholine (1 g)
Trial: 2959917
Drug: Etretin 40
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretin 40 mg
Trial: 2959917
Drug: Etretinate 40
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate 40 mg
Trial: 31695168
Drug: Escitalopram, Sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram, Sertraline, Venlafaxine-XR (antidepressants)
Trial: 30091952
Drug: Golimumab in
RxNorm normalized name: golimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab in combination with methotrexate
Trial: 31908843
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with methotrexate
Trial: 28647668
Drug: Early improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early improvement (Hamilton Depression Rating Scale reduction > 20% after 14 days of treatment)
Trial: 25808818
Drug: Favipiravir (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir (acute administration for 1 day)
Trial: 25808818
Drug: Favipiravir (extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir (extended administration for 6 days)
Trial: 25808818
Drug: Favipiravir co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir co-administration
Trial: 20501622
Drug: Rapamycin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin 3 mg
Trial: 18707820
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin (area under the curve of 2) during RT
Trial: 16517502
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of DHA and 150 mg of EPA
Trial: 12650950
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg)
Trial: 8800165
Drug: Early extubation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early extubation group (n = 60; 15 micrograms.kg‐1 fentanyl and 2 to 6 mg.kg‐1.hour‐1 propofol and isoflurane)
Trial: 8800165
Drug: Conventional extubation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional extubation group (n = 60; 50 micrograms.kg‐1 fentanyl and 0.1 mg.kg‐1 midazolam and isoflurane)
Trial: 1386224
Drug: Morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2 mg with Sufentanil 25 micrograms
Trial: 26868507
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day)
Trial: 23632408
Drug: 3.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5% lidocaine gel applied without pressure
Trial: 22094937
Drug: Epirubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (75 mg/m²) + Paclitaxel (175 mg/m²)
Trial: 22094937
Drug: Epirubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (75 mg/m²) + Paclitaxel (155 mg/m²) + Capecitabine (825 mg/m² BID for 14 days)
Trial: 19016569
Drug: 20-mL syringe
RxNorm normalized name: thiopental
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-mL syringe with vacuum obtained by a hand-grip device (Group 1)